Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKB264 plus local radiotherapy in EGFR-TKI–resistant NSCLC
ChiCTR2600126966Phase 2Not yet recruiting
- Sponsor
- The Affiliated Hospital of Jiaxing University
- Start
- Jun 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab tirumotecan in non-small cell lung cancer (NSCLC), sponsored by The Affiliated Hospital of Jiaxing University. Primary endpoint: Objective response rate (ORR). Planned start Jun 2026; status: not yet recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600126966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600126966.